NSB
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
$0.0590
▲ +1.72%
Market cap
$23M
Turnover
$1,316
Last price
$0.0590
Day change
+1.72%
Announcements
8
Range, past year
Open 0.150 · Low 0.047 · Now 0.059 · High 0.260
Open NSB in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
NSB momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
20/100
Wyckoff phase
Downtrend4d
Trend stage
Breakdown
1 Day
+1.7%
1 Week
-4.8%
1 Month
-4.8%
1 Year
-63.1%
RSI
46
Avg daily range
4.3%
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD scores 20 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 4 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- Thin liquidity
- Risk rating: High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsNSB announcements
Recent price-sensitive releases.
- 2026-10-01 Leading CRO Appointed for Phase 2 Crohn's Trial Progress Report
- 2026-08-25 2026 Annual Report & Appendix 4E Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-28 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-05-26 Remarkable Results from Patients treated with StemSmart
- 2026-05-25 Trading Halt
- 2026-04-30 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.